The genetic changes that decide whether a slow-growing blood cancer will one day turn aggressive can show up years before any symptoms, a long-term study has found — raising the prospect of catching high-risk patients far earlier.
Researchers at the Wellcome Trust Sanger Institute, with Cambridge University Hospitals, studied myeloproliferative neoplasms (MPNs), rare chronic blood cancers that begin in the bone marrow. They followed 30 patients over time — some for up to 25 years — analyzing more than 450 blood samples and nearly 8,000 test results through repeated genomic sequencing. The findings were published July 31, 2026 in Cancer Discovery.
What they saw
Patients whose disease later progressed steadily accumulated new DNA mutations, while those who stayed stable picked up few additional changes. In other words, the genome carried an early signal of trouble. “Mutations linked to future progression may be detectable long before symptoms worsen or standard clinical tests reveal a major change,” the researchers said.
Why it matters
Regular genomic monitoring could, in principle, identify which patients are heading toward more dangerous disease — allowing earlier intervention for those at risk while sparing stable patients unnecessary treatment. One participant, diagnosed in 1992 with essential thrombocythemia, progressed to myelofibrosis only after more than three decades of care, illustrating how slowly — and unevenly — these cancers can evolve. The approach is not yet routine clinical practice, but it points toward more personalized monitoring of chronic blood cancers.